Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in neovascular age-related macular degeneration (CLEAR-IT 2)
NCT00320788Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2006
- Primary completion
- Jun 2008
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Started Apr 2006; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00320788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320788.